Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.74 is 93% below its 5-year average of -2.46, near the low end of its 5-year range (-4.74–-0.83).
28.63% below its 12-month average of -3.69.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:19:04.124Z. Historical observations retain their original dates. Historical series through 2015-11-10.
EARNINGS PER SHARE (EPS)
-4.74
EARNINGS PER SHARE (EPS) AVG TTM
-3.69
EARNINGS PER SHARE (EPS) AVG 3Y
-3.04
EARNINGS PER SHARE (EPS) AVG 5Y
-2.46
EARNINGS PER SHARE (EPS) AVG 10Y
-2.03
EARNINGS PER SHARE (EPS) AVG 15Y
-1.73
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.63%
CURRENT VS 3Y AVG
-55.92%
CURRENT VS 5Y AVG
-92.68%
CURRENT VS 10Y AVG
-133.08%
CURRENT VS 15Y AVG
-173.76%
CURRENT VS 20Y AVG
N/A
Xenon Pharmaceuticals Inc.
Market Cap
$3.50B
Earnings Per Share (EPS)
-4.74
TTM Avg
-3.69
3Y Avg
-3.04
5Y Avg
-2.46
Market Cap
$3.47B
Earnings Per Share (EPS)
-4.29
TTM Avg
-3.30
3Y Avg
-2.99
5Y Avg
-2.52
Market Cap
$3.45B
Earnings Per Share (EPS)
-1.94
TTM Avg
-2.32
3Y Avg
-2.00
5Y Avg
-1.79
Market Cap
$3.55B
Earnings Per Share (EPS)
1.40
TTM Avg
0.58
3Y Avg
-0.09
5Y Avg
-0.36
Market Cap
$3.54B
Earnings Per Share (EPS)
-0.43
TTM Avg
-2.51
3Y Avg
-3.24
5Y Avg
-3.00
Market Cap
$3.44B
Earnings Per Share (EPS)
-1.17
TTM Avg
-1.00
3Y Avg
-1.15
5Y Avg
-1.50
Market Cap
$3.57B
Earnings Per Share (EPS)
-0.85
TTM Avg
-1.03
3Y Avg
-1.09
5Y Avg
-1.06
Market Cap
$3.38B
Earnings Per Share (EPS)
2.22
TTM Avg
1.84
3Y Avg
0.49
5Y Avg
-0.14
Market Cap
$3.33B
Earnings Per Share (EPS)
N/A
TTM Avg
-87.94
3Y Avg
-87.94
5Y Avg
-87.94
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | $3.50B | -4.74 | -3.69 | -3.04 | -2.46 |
| Celcuity Inc. (CELC)vs › | $3.47B | -4.29 | -3.30 | -2.99 | -2.52 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.45B | -1.94 | -2.32 | -2.00 | -1.79 |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 1.40 | 0.58 | -0.09 | -0.36 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | -0.43 | -2.51 | -3.24 | -3.00 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -1.17 | -1.00 | -1.15 | -1.50 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -0.85 | -1.03 | -1.09 | -1.06 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 2.22 | 1.84 | 0.49 | -0.14 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A | -87.94 | -87.94 | -87.94 |
| CareDx, Inc (CDNA)vs › | $3.32B | 2.07 | 0.30 | -1.10 | -0.90 |
Trailing EPS (TTM)
$-4.74
Forward EPS (Est.)
$-4.60
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.36 |
| 2024-12-31 | -3.01 |
| 2023-12-31 | -2.73 |
| 2022-12-31 | -2.06 |
| 2021-12-31 | -1.77 |
| 2020-12-31 | -0.83 |
| 2019-12-31 | -1.54 |
| 2018-12-31 | -1.78 |
| 2017-12-31 | -1.71 |
| 2016-12-31 | -1.48 |
| 2015-12-31 | -1.10 |
| 2014-12-31 | 0.94 |
| 2013-12-31 | 0.42 |
| 2012-12-31 | -3.23 |
| 2011-12-31 | -9.02 |
